LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Viemed Healthcare Announces Date and Time for Conference Call

February 20, 2024 | Last Trade: US$6.41 0.11 -1.69

LAFAYETTE, La., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Year End Conference Call on Thursday, March 7, 2024 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)
+1-201-689-8451 (International)

Financial professionals are invited to call in to register in advance to ask questions. To pre-register as a qualified caller, please e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. by 12:00 p.m. ET Wednesday, March 6, 2024.

Live Audio Webcast

Following the live call, a replay will be available in the Investor Relations section of the Company’s website, www.viemed.com

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page